Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 3/20 | 0.75 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.75 |
| ▸ | LNPEP | Q9UIQ6 | 5/20 | 0.73 |
| ▸ | ANPEP | P15144 | 2/20 | 0.73 |
| ▸ | REN | P00797 | 8/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24849923 | 0.94 | REN (0.78) | AGTR1AGTR2LNPEPANPEPREN | |
| Angiotensin Iv SCHEMBL27169570 | 0.93 | LNPEP (0.82) | AGTR1AGTR2LNPEPANPEPREN | |
| Angiotensin Iv SCHEMBL10066237 | 0.93 | LNPEP (0.82) | AGTR1AGTR2LNPEPANPEPREN | |
| SCHEMBL4738788 | 0.90 | AGTR1 (0.69) | AGTR1AGTR2LNPEPANPEPREN | |
| SCHEMBL31332289 | 0.89 | AGTR2 (0.91) | AGTR1AGTR2LNPEPREN | |
| SCHEMBL29770563 | 0.88 | LNPEP (0.74) | AGTR1AGTR2LNPEPANPEPREN | |
| SCHEMBL29701255 | 0.88 | SLC6A2 (0.63) | AGTR1AGTR2LNPEPANPEPREN | |
| Angiotensin Ii SCHEMBL31477824 | 0.87 | AGTR2 (0.98) | AGTR1AGTR2 | |
| Angiotensin Ii SCHEMBL21811603 | 0.86 | AGTR2 (1.00) | AGTR1AGTR2 | |
| Angiotensin Ii SCHEMBL29361852 | 0.86 | AGTR2 (1.00) | AGTR1AGTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4691485-A1 | MUCOSAL ADJUVANT | Toyama Prefecture (JP) | 2026-02-11 | — | — | EP | claimed |
| WO-2024204419-A1 | MUCOSAL ADJUVANT | 富山県 | 2024-10-03 | — | — | WO | claimed |
| US-20220160905-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-05-26 | — | — | US | claimed |
| EP-4691485-A1 | MUCOSAL ADJUVANT | Toyama Prefecture (JP) | 2026-02-11 | — | — | EP | disclosed |
| EP-4676563-A1 | DEVICE AND METHOD FOR PURIFYING BODY FLUIDS BY REMOVING ANGIOTENSIN-SPECIFIC ANTIBODIES | Klingenberg, Georg Jochen (DE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4021571-B1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-10-08 | — | — | EP | disclosed |
| EP-4552649-A2 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2025-05-14 | — | — | EP | disclosed |
| US-20250000932-A1 | DIAGNOSIS AND TREATMENT OF VASODILATORY SHOCK | UNIVERSITY OF MARYLAND, BALTIMORE | 2025-01-02 | — | — | US | disclosed |
| WO-2024233922-A2 | PYRIDINE-PIPERAZINE-BASED SCAFFOLDS AS HIGHLY POTENT AND SELECTIVE NEUROLYSIN ACTIVATORS | TEXAS TECH UNIVERSITY SYSTEM (US) | 2024-11-14 | — | — | WO | disclosed |
| WO-2024204419-A1 | MUCOSAL ADJUVANT | 富山県 | 2024-10-03 | — | — | WO | disclosed |
| WO-2024188952-A1 | DEVICE AND METHOD FOR PURIFYING BODY FLUIDS BY REMOVING ANGIOTENSIN-SPECIFIC ANTIBODIES | KLINGENBERG GEORG JOCHEN (DE) | 2024-09-19 | — | — | WO | disclosed |
| EP-4427767-A1 | DEVICE AND METHOD FOR EXTRACORPOREAL BLOOD WASHING WITH SEPARATION OF ANGIOTENSIN-SPECIFIC ANTIBODIES | Klingenberg, Georg (DE) | 2024-09-11 | — | — | EP | disclosed |
| CN-116731181-B | Anti-human CD10 protein rabbit monoclonal antibody and application thereof | 武汉爱博泰克生物科技有限公司 | 2024-01-12 | — | — | CN | disclosed |
| CN-116731181-A | Anti-human CD10 protein rabbit monoclonal antibody and application thereof | 武汉爱博泰克生物科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| US-20220307065-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-09-29 | — | — | US | disclosed |
| US-20220273757-A1 | METHODS FOR ADMINISTERING ANGIOTENSIN II BY MONITORING RENIN LEVELS | LA JOLLA PHARMA LLC (US) | 2022-09-01 | — | — | US | disclosed |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-07 | — | — | US | disclosed |
| EP-4021571-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR TREATMENT OF SHOCK | 4TEEN4 Pharmaceuticals GmbH (DE) | 2022-07-06 | — | — | EP | disclosed |
| CN-114556100-A | Therapy guidance and/or therapy monitoring for treatment of shock | 4TEEN4制药有限公司 | 2022-05-27 | — | — | CN | disclosed |
| US-20220160905-A1 | FLUORINATION METHOD | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160905-A1 | FLUORINATION METHOD | AFF2, AFF1, AFF4 | AGTR1 2311/4885AGTR2 1687/4885LNPEP 2308/4885 |
| US-20220211798-A1 | THERAPY GUIDANCE AND/OR THERAPY MONITORING FOR A TREATMENT WITH ANGIOTENSIN-RECEPTOR-AGONIST AND/OR A PRECURSOR THEREOF | DPP3, ACE, FABP3 | AGTR1 5/4885AGTR2 9/4885LNPEP 743/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.